RxDoctor Payments Data

Nancy Holloway

Nurse Practitioner · Houston, TXNPI 1508850942

Payments from drug & device makers

$2,513in general payments, 2019–2025

Across 100 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$959
  • Axonics, Inc.$267
  • Urovant Sciences Inc$262
  • Astellas Pharma US Inc$213
  • AbbVie$209
  • Coloplast$129
  • plus $474 from 9 others

What the payments were for

  • Food & beverage$2,42096%
  • Education$934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,513 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$65,089
Medicare patients
288
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron163$110,291
MyrbetriqMirabegron73$52,117
Mirabegron ErMirabegron17$9,414
Estradiol (Twice Weekly)Estradiol93$8,507
PremarinEstrogens, Conjugated17$7,345
LyllanaEstradiol48$6,068
Estradiol84$3,990
ProgesteroneProgesterone, Micronized55$2,652
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst141$2,325
Methenamine Hippurate18$2,032
Metronidazole41$1,261
Oxybutynin Chloride ErOxybutynin Chloride22$322
Terconazole12$292
Cephalexin31$232
Fluconazole42$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$959$110,291163 claims
Astellas Pharma US IncMyrbetriq$213$52,11773 claims
PfizerPremarin$55$7,34517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →